reSET-O, the first PDT to receive Breakthrough Designation and authorized by FDA in December 2018, is an 84-day Prescription Digital Therapeutic (PDT) for Opioid Use Disorder (OUD) intended to increase retention of patients in outpatient treatment by providing cognitive behavioral therapy (CBT), as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician.

EndeavorRx is an ADHD treatment for kids aged 8-12. It’s delivered through an immersive video game experience on mobile devices. Created by world-class neuroscientists and award-winning game designers, it targets areas of the brain that play a key role in attention function. As an FDA-authorized medical device, EndeavorRx must be prescribed by a healthcare professional. It should be considered for use as part of a therapeutic program.

For individuals with substance use disorder (SUD), reSET® is the first FDA-authorized prescription digital therapeutic that’s proven to increase abstinence and treatment retention. Patients download the reSET app to their smartphone for secure, discreet, convenient access to therapy, interactive learning, and support.

It's time to change the way medicine is designed, delivered and experienced. At Akili, we believe effective medicine for serious illnesses can also be fun and engaging. We're creating a new class of digital medicines for people living with cognitive impairment, delivered through captivating video game experiences.